<DOC>
	<DOCNO>NCT00996203</DOCNO>
	<brief_summary>This open-label single arm study evaluate efficacy safety tocilizumab add traditional disease-modifying antirheumatic drug ( DMARDs ) patient moderate severe active rheumatoid arthritis inadequate response DMARDs . Patients receive tocilizumab 8 mg/kg intravenous infusion every 4 week 24 week , addition current non-biologic DMARDs stable dos . Anticipated time study treatment 24 week , target sample size 200 .</brief_summary>
	<brief_title>A Study Tocilizumab Added DMARDs Patients With Moderate Severe Rheumatoid Arthritis Inadequate Response DMARDs .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient , &gt; /= 18 year age moderate severe active rheumatoid arthritis &gt; /=6 month duration inadequate clinical response current nonbiologic DMARDs current DMARDs must stable dose 8 week prior study entry oral corticosteroid ( &lt; /=10mg/day prednisone equivalent ) NSAIDs must stable dose &gt; /=4 week prior screen rheumatic autoimmune disease RA history current inflammatory joint disease RA previous treatment biologic DMARD functional class IV define ACR classification intraarticular parenteral corticosteroid within 6 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>